SCHEMBL725156

SCHEMBL725156

COCCNC(=O)c1cccc(-c2ccnc3cc(-c4cc(OC)c(OC)c(OC)c4)oc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 2/20 0.49
POLB P06746 1/20 0.45
KMT2A Q03164 2/20 0.44
BRD4 O60885 1/20 0.44
HPGD P15428 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 1/20 0.41
TP53 P04637 1/20 0.41
PDE4C Q08493 1/20 0.41
BRAF P15056 1/20 0.41
LOX P28300 2/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
AURKA O14965 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
MET P08581 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
TEK Q02763 1/20 0.41
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723443 0.93 FYN (0.58) FYNPOLBKMT2ABRD4PDE4C
SCHEMBL723071 0.91 FYN (0.54) FYNRAD52
SCHEMBL15210451 0.90 FYN (0.43) FYNPOLBKMT2ABRD4HPGD
SCHEMBL722768 0.89 FYN (0.49) FYNKMT2ATDP1LCKMET
SCHEMBL16817209 0.89 FYN (0.43) FYNHPGDTP53BRAFLOX
SCHEMBL15210396 0.88 FYN (0.44) FYNPOLBKMT2ABRD4HPGD
SCHEMBL15210397 0.88 FYN (0.44) FYNPOLBKMT2ABRD4HPGD
SCHEMBL15210650 0.88 FYN (0.44) FYNPOLBKMT2ABRD4HPGD
SCHEMBL724106 0.88 PDE4C (0.44) FYNHPGDPDE4CHSD17B10L3MBTL1
SCHEMBL15210436 0.87 FYN (0.46) FYNPOLBHPGDPDE4CKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB FYN 33/4885POLB 3460/4885KMT2A 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.